Melanotan 1 vs Melanotan 2: A Scientific Comparison

Melanotan I and Melanotan II are two synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH), a natural peptide hormone that regulates skin pigmentation. Despite similar names, they are distinct molecules with different structures, potencies and effect profiles. The shared name reflects their common origin — both were developed from research on melanocortin peptides at the University of Arizona in the late 1980s and 1990s — but treating them as interchangeable is a frequent and important mistake.

Melanotan I, now known by its International Nonproprietary Name afamelanotide, is a linear peptide that closely mirrors the structure of natural α-MSH. It has since become an approved pharmaceutical, marketed as Scenesse® for a rare inherited light-sensitivity disorder. Melanotan II, by contrast, is a shorter cyclic peptide engineered to be far more potent and stable, and it was never developed into an approved medicine. Instead, it became widely known as a black-market "tanning injection."

Both peptides act on the family of melanocortin receptors (MC1R through MC5R), but they do so with very different selectivity. This single difference — how broadly each peptide activates the receptor family — explains almost everything that distinguishes their real-world effects, from the tan they produce to the side effects users report. To understand what are peptides and how small structural changes reshape their behavior, see our overview of what peptides are.

This comparison walks through their chemistry, mechanism, pigmentation effects, the reasons Melanotan II produces sexual and appetite effects, and — critically — the regulatory and safety differences that matter most for anyone researching these compounds. This content is for educational purposes only and does not constitute medical advice.

The clearest way to distinguish the two peptides is by their molecular architecture. Melanotan I (afamelanotide) is a linear tridecapeptide — 13 amino acids arranged in a chain — with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. It is essentially natural α-MSH with two key substitutions: norleucine (Nle) at position 4 and D-phenylalanine (D-Phe) at position 7. These changes protect the peptide from rapid enzymatic breakdown and increase its potency while preserving the overall shape of the parent hormone.

Melanotan II is a much smaller and more radically redesigned molecule: a cyclic heptapeptide with the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. A lactam bridge between the aspartate and lysine side chains locks the peptide into a rigid ring. This cyclization dramatically improves metabolic stability and receptor-binding affinity, making Melanotan II a "superpotent" agonist — but the same ring also removes the fine selectivity that the linear structure preserves.

These structural differences translate into concrete numbers. Melanotan I has a molecular formula of C₇₈H₁₁₁N₂₁O₁₉ and a molecular weight of roughly 1646.85 g/mol, consistent with its 13-residue length. Melanotan II is considerably smaller, with a formula of C₅₀H₆₉N₁₅O₉ and a molecular weight of about 1024.18 g/mol.

The lesson is that these are not "version 1" and "version 2" of one drug. They are two separate peptides that happen to share a lineage. As with many peptide analogs, small edits — a cyclization here, a residue swap there — produce large downstream differences in stability, potency and, most importantly, receptor selectivity. Readers new to this terminology may find our peptide glossary helpful for terms like "cyclic peptide" and "agonist."

Both peptides exert their effects through the melanocortin receptor family, a group of five G-protein-coupled receptors (MC1R–MC5R) distributed across different tissues. Each receptor governs distinct physiology: MC1R controls pigmentation in skin melanocytes, MC3R and MC4R regulate energy balance, appetite and sexual function in the brain, and MC5R is involved in exocrine gland activity. Natural α-MSH activates several of these, but the body tightly controls its release and rapid breakdown.

Melanotan I is designed to behave much like α-MSH, with meaningful selectivity toward MC1R-driven pigmentation while being far more resistant to degradation. Its linear structure preserves a binding profile close to the natural hormone, which is why its dominant, intended effect is increased melanin production with comparatively fewer central nervous system effects.

Melanotan II, because of its rigid cyclic structure, is a non-selective, high-affinity agonist that activates MC1R, MC3R, MC4R and MC5R with substantial potency. In an early pilot Phase I study, Melanotan II was described as a "superpotent" melanotropic peptide precisely because it engaged the receptor system so broadly and strongly. This broad activation is the single most important fact for understanding why the two peptides behave so differently in the body.

In practical terms, selectivity is destiny. Melanotan I hits mainly the pigmentation pathway; Melanotan II hits pigmentation plus the brain circuits that govern arousal and appetite. That is not a bonus feature — it is the mechanistic root of Melanotan II's most notorious side effects, discussed below. Neither peptide should be assumed safe simply because it is "just a tanning peptide"; both act on receptor systems with wide physiological reach.

The shared, headline effect of both peptides is stimulation of melanogenesis — the production of melanin by melanocytes in the skin. By activating MC1R, both compounds push melanocytes toward producing more eumelanin, the darker pigment associated with tanning and, biologically, with some degree of photoprotection. This is the effect that made both peptides famous under the nickname "the tanning injection."

For Melanotan I, this pigmentation effect is the therapeutic goal. In its approved form, afamelanotide increases melanin density to help protect patients with erythropoietic protoporphyria (EPP) — a rare disorder in which sunlight causes severe pain — by allowing them to tolerate more light exposure. Clinical trials, including a controlled study published in the New England Journal of Medicine, demonstrated increased pain-free light exposure in EPP patients receiving afamelanotide implants.

Melanotan II also produces tanning, and because it is more potent and non-selective, users often report faster or more pronounced darkening. However, the pigmentation from Melanotan II frequently comes with the darkening of existing moles (nevi) and the appearance of new pigmented lesions — a cosmetic and dermatological concern rather than a benefit. Increased freckling and uneven pigmentation are also commonly reported.

A crucial caveat applies to both: a melanocortin-induced tan is not equivalent to sun protection and does not eliminate the risk of UV damage or skin cancer. Neither peptide has been shown to be a safe substitute for sunscreen or sensible sun behavior. Anyone considering these compounds for cosmetic tanning should understand that the evidence base for safe, long-term cosmetic use is essentially absent. Consult a dermatologist or other qualified healthcare professional before drawing any conclusions about pigmentation agents.

One of the most striking practical differences between the two peptides is that Melanotan II reliably produces effects far beyond tanning — most notably spontaneous erections, increased sexual arousal, appetite suppression and nausea — while Melanotan I largely does not. This difference is not accidental; it is a direct consequence of receptor selectivity.

Because Melanotan II strongly activates MC4R in the central nervous system, it stimulates the brain circuits involved in sexual response and satiety. Early human studies noted this vividly: research on Melanotan II in men with erectile dysfunction reported erectile responses as a prominent effect, and this observation directly led to the development of bremelanotide (PT-141), a related MC4R-focused peptide that was later approved for a specific female sexual-dysfunction indication. In other words, Melanotan II's "side effect" became the basis of a separate drug.

Appetite suppression and nausea arise from the same MC4R and MC3R activation involved in energy balance. Many users of Melanotan II report reduced hunger and transient nausea, particularly after early doses. Facial flushing and yawning are also commonly described and reflect broad melanocortin signaling.

Melanotan I, being more selective for the pigmentation pathway, produces these central effects far less prominently, which is part of why it was a more suitable candidate for pharmaceutical development. The takeaway for anyone comparing the two: if a peptide is being discussed for its libido or appetite effects, that is Melanotan II-type pharmacology, and it comes bundled with the broader safety concerns of non-selective melanocortin activation. These are not effects to be sought casually, and none of this should be read as an endorsement of self-experimentation.

Regulatory status is arguably the sharpest dividing line between the two peptides, and it is frequently misunderstood. Melanotan I (afamelanotide) is an approved pharmaceutical. Marketed as Scenesse® by Clinuvel, it received European Medicines Agency approval in 2014 and U.S. FDA approval in 2019, both for the prevention of phototoxicity in adults with erythropoietic protoporphyria. It is administered as a controlled subcutaneous implant by trained clinicians — not as a self-injected vial.

Crucially, that approval is narrow. Afamelanotide is not approved for cosmetic tanning or for general use, and it is not available over the counter. Its legitimate supply chain is limited to specialist EPP treatment centers.

Melanotan II has never been approved for human use in any major jurisdiction. Regulators including the U.S. FDA, the UK MHRA and various European agencies have issued warnings against products containing it. It is typically sold online as a "research chemical" or "not for human consumption" product, which places it in a legal gray area or renders it outright unlawful to sell for human use depending on the country. Its legal status varies significantly by jurisdiction.

Because of this unregulated status, Melanotan II products carry no guarantee of identity, purity, sterility or dose accuracy. If any supplier price is discussed, treat it strictly as research-supply information rather than an endorsement of human use — for example, Melanotan II is listed by some research suppliers around 27.96 USD per 10 mg vial, but pricing and availability change frequently and legality remains the user's responsibility. Anyone researching these compounds should confirm the current legal status in their own country and consult our medical disclaimer.

Neither peptide is free of risk, but their safety profiles differ substantially because of selectivity and, critically, because of how each is supplied. For Melanotan I (afamelanotide), safety data come from controlled clinical trials and post-approval monitoring. Reported effects in that regulated context include nausea, headache, fatigue, and the expected skin darkening. Because it is administered under medical supervision as an implant, dosing and monitoring are controlled.

Melanotan II presents a broader and less predictable risk profile. Commonly reported effects include nausea and vomiting, facial flushing, spontaneous erections, appetite loss, and darkening of moles and freckles. More concerning are the dermatological signals: case reports in the medical literature describe changes in melanocytic nevi and, in at least one report, melanoma occurring in association with Melanotan II use. While a causal link is not established, the appearance of new or changing pigmented lesions is a recognized red flag that warrants dermatological evaluation.

Rare but serious events have also been reported with Melanotan II, including cases of rhabdomyolysis and other systemic reactions. Layered on top of the pharmacology is a product-quality problem: because Melanotan II is sold unregulated, injectable products may be non-sterile, mislabeled, under- or over-dosed, or contaminated — introducing infection risk and dosing uncertainty entirely separate from the peptide's intrinsic effects.

The medical literature has repeatedly flagged Melanotan II as an emerging drug of concern precisely because it combines potent, non-selective pharmacology with an unregulated supply chain and self-administration. There is no established safe dose for cosmetic use, and long-term safety data are lacking. This section is not a usage guide; it is a summary of documented risks. Anyone noticing changing moles, persistent nausea, or any unusual symptom should stop and seek medical care promptly.

When weighing the two peptides, the quality and quantity of human evidence differ enormously. Melanotan I (afamelanotide) has been through the full arc of pharmaceutical development: randomized controlled trials, regulatory review, and ongoing pharmacovigilance. The controlled EPP trials — including the multicenter study published in the New England Journal of Medicine — provide genuine clinical evidence for a defined indication in a defined patient population.

It is important to be precise about what that evidence covers. The afamelanotide trials validate its use for erythropoietic protoporphyria, not for cosmetic tanning in healthy people. So even the "well-studied" peptide is well-studied only for a narrow, rare condition. Extrapolating its favorable regulatory status to recreational tanning is not supported by the data.

Melanotan II has only limited early human data — small pilot and Phase I studies from the 1990s and early 2000s examining tanning and erectile effects — and no completed program establishing safety or efficacy for any approved use. Its development was effectively redirected: the sexual-function findings led to bremelanotide (PT-141), while Melanotan II itself was left behind as an unapproved compound that persists mainly through the gray market. As a result, the modern literature on Melanotan II is dominated by case reports of harm rather than trials of benefit.

The honest summary is asymmetric: Melanotan I has real but narrow clinical validation; Melanotan II has weak human evidence and a growing safety-signal literature. Neither justifies casual cosmetic use, and the difference in evidence should not be mistaken for a difference in casual safety. For general context on how peptides are studied and classified, see our introduction to peptides.

The table below consolidates the key differences discussed throughout this article. It is intended as an at-a-glance reference, not a recommendation to use either compound.

The overarching conclusion is that Melanotan I and Melanotan II should be thought of as two different drugs with a shared ancestry, not two strengths of one product. Melanotan I is a niche, approved therapy for a rare disease; Melanotan II is an unapproved, broadly acting peptide with a concerning safety and legal profile.

This article is for educational purposes only and is not medical advice. These peptides are not approved for cosmetic use, legal status varies by jurisdiction, and the clinical evidence discussed applies to specific research and disease contexts rather than to general self-administration. Always consult a qualified healthcare professional before considering any melanocortin peptide.